AI: The Next Revolution In Medicine?

Jan 23, 2019

AI: The Next Revolution In Medicine?

Watch our CEO, Joanna Shields, as she takes the stage and returns to DLD 2019 - an event which is a source of great inspiration and hope.

Given the state of the world today, at BenevolentAI we think we could all benefit from a giant dose of optimism. We believe that unconventional thinking combined with purposeful technology can truly change outcomes in the world. And that is what Joanna touches upon during her talk to the audience at DLD.

Tagged:

More Posts

You Might Also Like

Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis

Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.

May 5, 2021

A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF

Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.

Apr 23, 2021

Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population

Apr 8, 2021

BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020

BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.

Mar 8, 2021

Tech Nation Visa: the gateway to world-leading UK tech jobs

Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.

Feb 19, 2021

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.

Feb 11, 2021